Page 2/2

Health Policy

Sanochemia Confirms the Turnaround and Returns to Profitability

Sanochemia reports a profit and puts the focus on market expansion. Revenue increased by 20 percent year-on-year.

May 13, 2011

Intercell: Sale Is No Longer Ruled Out

The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.

May 11, 2011

Lingelbach New CEO for Intercell

Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.

May 5, 2011

Intercell starts a confirmatory clinical study using the Vaccine Enhancement

Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches

May 4, 2011

Rethinking of Health Policy Required

Junge Wirtschaft (Young Business) demands more economic incentives for healthy lifestyles for employees. This should allow an increase in retirement age.

April 19, 2011

Sanochemia: Capital Increase Disappointing

The Austrian pharmaceutical company could not meet its own expectations regarding the capital increase. A strategic investor bailed out.

April 18, 2011

Intercell: Vaccine Development to Suspend

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

April 11, 2011

Intercell Announces next Steps of Development for Pseudomonas Vaccine

Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.

April 2, 2011

Record Sales for VAMED AG

The Austrian health care group was able to increase sales and EBIT by 15%. Orders on hand at over € 800m are record high.

March 25, 2011 · Updated: March 25, 2011; 03:24

Lannacher has Delivery Problems with Iodine Tablets

The Austrian pharmaceutical company manufactures the only potassium iodide tablets in the German-speaking area. Demand strongly exceeds production capacity.

March 18, 2011

Opportunities for Austrian Medical Technology in the UK

An Austrian study showed Austrian buinesses the opportunities offered by the British market: Austrian exports increased by 15% in 2010.

March 17, 2011

Massive Losses for Intercell

The Austrian pharmaceutical company today reported losses for 2010 amounting to € 255m. Operating cash flow has been strongly negative too.

March 2, 2011

Intercell Issues Convertible Bond

The Austrian pharmaceutical company Intercell starts offering of € 30.8m senior convertible debt financing.

February 23, 2011

Sanochemia: Strong Increase in EBIT

The Austrian pharmaceutical company today announced its figures for Q1. Earnings rise eight-fold.

February 18, 2011

Sanochemia Stays in the Red

Despite improvements in its financial data, the Austrian pharmaceutical company Sanochemia does not succeed in eliminating its losses

January 28, 2011

Humanomed to Expand to CEE/SEE

The Austrian Humanomed-Group, a health care company, sees potential to expand to countries in (South) Eastern Europe.

January 28, 2011

Pfizer Austria: First Sustainability Report Published

Pfizer Austria published its first sustainability report based on the recognized guidelines of the Global Reporting Initiative.

January 20, 2011

Sanochemia: Decrease in Sales, Decrease in Losses

The Vienna Stock Exchange listed manufacturer of pharmaceutical products could improve its results slighty.

January 3, 2011

Intercell Raises Authorized Capital

The Management Board of the Austrian biotechnology company is authorized to increase the share capital up to a nominal amount of € 855,000.00.

December 16, 2010

Serious setback for Intercell

The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.

December 14, 2010

Economic Chamber in Tokyo: Biotechnology as an Opportunity

The President of the Vienna Economic Chamber, Brigitte Jank, sees above all great opportunities for Austria in Japanese biotechnology and pharmaceutical industries.

December 6, 2010

Expansion Potential of Austrian Pharmaceutical Industry in Japan

Japanese pharmaceutical companies need new products and international cooperation. An opportunity for local companies.

December 1, 2010

Economic Chamber President Leitl Demands Financial Transaction Tax

There is consensus between the Presidents of the Economic Chamber and the Federation of Trade Unions.

November 23, 2010

F-Star Acquired Major Order

The Vienna-located f-star and Boehringer Ingelheim to collaborate in discovery and development of therapeutic antibodies.

November 23, 2010

Roche Lays Off 400 Jobs in Styria

The Swiss pharmaceutical group reduces its international workforce by 6%: a setback for the region.

November 18, 2010

Standard & Poor’s: Austria's Credit Rating at Risk

The reasons for such gloomy prospects are not problems with the banks or domestic companies, but rather the demographic situation threaten Austria's credit rating.

November 11, 2010

Criticism of Austria's Allocation of Subsidies

Both the volume and the organization of the allocation of subsidies are susceptible of improvement, experts say.

October 21, 2010

Humanomed Takes Over Management of Private Clinics in the CEE Region

The know-how of the private clinic operator is to be exported. The objective is not to only give advice, but also to take over the management of private clinics in the CEE region.

September 28, 2010